Sage Journals: Discover world-class research

Abstract

Keywords

Leprosy immune

Get full access to this article

View all access options for this article.

References

Sensi

. History of the development of rifampin. Rev Infect Dis 1983; 5: S402–406.

Chang

Leung

Grosset

et al.

Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: 997–1007.

Bayer

Wilkinson

. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995; 345: 1545e8–1545e8.

World Health Organization. WHO recommended MDT regimens. Geneva: WHO. Available at: http://www.who.int/lep/mdt/regimens/en/ (accessed 29 October 2016).

Havey

Cserti-Gazdewich

Sholzberg

et al.

Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampicin. Am J Trop Med Hyg 2012; 86: 264–267.

Martinez

Muniz

Domingo

. Evidence implicating rifampin-independent antiplatelet antibodies in the pathogenesis of rifampin-induced immune thrombocytopenia. Clin Infect Dis 1994; 19: 351–353.

Denis

Robert

Johanet

et al.

[Immunoallergic complication induced by rifampicin with disseminated intravascular coagulation]. Presse Med 1983; 12: 1479–1481.

Cheng

Cheung

. Disseminated intravascular coagulopathy associated with rifampicin. Tubercle 1991; 72: 2913–2913.

Allan WGL, Singh D, et al. A controlled clinical trial of small weekly doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: a second report: the results at 12 months. Tubercle 1974; 55: 193–210.

10.

Costiniuk

McCarthy

Talreja

et al.

Acute renal failure and disseminated intravascular coagulation associated with rifampin in tuberculosis treatment. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 2011; 15: 421–421.

11.

Soltani

Saidi

Haghverdy

et al.

Acute interstitial nephritis, hepatitis, hemolysis due to rifampin: a case report. J Iran Clin Res 2015; 1: 54–57.

12.

Luzzati

Giacomazzi

Franchi

et al.

Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis. South Med J 2007; 100: 854–856.

13.

Namisato

Ogawa

. Serious side effects of rifampin on the course of WHO/MDT: a case report. Int J Lepr Mycobact Dis Off Organ Int Lepr Assoc 2000; 68: 277–282.

Rifampicin-induced immune allergic reaction

Abstract

Keywords

Get full access to this article

References